The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
Open accessAbstract
Background The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours.Methods Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m 2 (maximum of 100 mg) twice daily. The primary endpoint was objective response as assessed by local investigators in an intention-to-treat analysis. Contributing trials are registered with ClinicalTrials.gov, NCT02122913 (active not recruiting), NCT02637687 (recruiting), and NCT02576431 (recruiting).Findings Between May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two [<1%]). No treatment-related deaths occurred.Interpretation These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible.Funding Bayer and Loxo Oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, entrectinib and lartotrectinib have demonstrated activity in patients with solid tumors with NTRK fusion”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“In this trial, 8 of 159 patients had colon cancer”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“with a median duration of 3.7 months.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“4 patients with colon cancer had a response to therapy”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“and the FDA has approved their use for these patients.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Two therapies, larotrectinib and entrectinib, are FDA-approved for use in CRC with NTRK mutation.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Based on the efficacy across tumor types, larotrectinib was FDA-approved for tumors with NTRK fusions, including CRC.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationAlectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. E. D. C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,521
Self-citationSkálová, A., Vaněček, T., Šíma, R., Laco, J., Weinreb, I., Perez‐Ordoñez, B., Stárek, I., Geierová, M., Simpson, R. H., Passador‐Santos, F., et al. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181d9efcc · Cited by 1,017
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
Tognon, C. E., Knezevich, S. R., Huntsman, D. D., Roskelley, C. D., Melnyk, N., Mathers, J. A., Becker, L. E., Carneiro, F., Macpherson, N. A., Horsman, D. E., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00180-0 · Cited by 908
Drilon, A. E. D. C., Siena, S., Ou, S. I., Patel, M. R., Ahn, M., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 833
Self-citation
Research works printed but not linked: 1
- Geoerger, 2019, Larotrectinib efficacyand safety in pediatric patients with TRK fusion cancer, Pediatr Blood Cancer, 66, S4
Cited by
Sorted by citations
Items 801–900 of 1,000
Ortiz, M. V., Wens, F. S. P. L., Hong, A. L., Quarello, P., Verschuur, A. C., Tracy, E. T., Daw, N. C., Dome, J. S., Walz, A. L., Sprokkerieft, J., et al. (2026) · Nature Reviews Urology · doi:10.1038/s41585-025-01117-4 · Cited by 1
TRK inhibitors in cancer therapeutics: Recent advances and future perspectives
Liu, H., Sun, Y., Wang, Y.-P., Zhang, X., Guo, S., Wang, L., Meng, F., & Zhang, T.-J. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109534 · Cited by 1
Komninos, D., Psarros, E., Theochari, E., Tsirikos, G., Sampsonas, F., & Tzouvelekis, A. (2026) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2026.2631816 · Cited by 1
Oncogenicity and Therapeutic Implications of Molecular Biomarkers in Colorectal Carcinoma
Evans, M. G., & Hechtman, J. F. (2026) · Surgical pathology clinics · doi:10.1016/j.path.2026.01.010 · Cited by 1
Dowdell, A. K., Ward, T., Hamilton, L., Weerasinghe, R. K., Schnettler, E. K., Sathyan, P., Roos, A., Wagner, J. T., Welle, J. T., Meng, R. C., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1764392 · Cited by 1
Zhan, Z.-J., Chen, S., Chen, L., Chang, S., & Huang, P. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105329 · Cited by 1
Wang, J., Jiang, L.-L., Wang, M., & Li, Y.-L. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s600434 · Cited by 1
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2025
Ahmed, A., Mercier, S. L., Ramjeesingh, R., Thompson, R. H., Bastin, D. J., Spadafora, S., Megid, T. B. C., Djedovic, V., Taggar, A. S., Falkson, C. B., et al. (2026) · Current Oncology · doi:10.3390/curroncol33040228 · Cited by 1
Lin, S.-T., Lai, H.-C., Schill, P., & Yeh, C. (2026) · Tumor Discovery · doi:10.36922/td025520129 · Cited by 1
Onesti, C. E., Casini, B., Chiara, A. D., Fausti, V., Luksch, R., Milano, G. M., Palmerini, E., Vari, S., Ceddia, S., Riva, F., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1641281 · Cited by 1
Molecularly Guided Therapy in Hepatobiliary Cancers
Adeva, J., Kalluri, V. S., Saj, F., Modrego, A., & Javle, M. M. (2026) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2026.05.005 · Cited by 1
Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review
Fan, J., Ni, Y., Ni, R., Pan, G., Peng, Y., Zhou, L., Jing, R., Song, P., & Luo, D. (2026) · Current Treatment Options in Oncology · doi:10.1007/s11864-026-01400-5 · Cited by 1
Pancreatic Cancer: Translating Tumor Biology into Actionability
Balogun, F. O., Sherman, M. H., Park, W., Soares, K. C., Reyngold, M., Schoenfeld, J. D., Singhal, A., Iacobuzio–Donahue, C. A., & O'Reilly, E. M. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-2014 · Cited by 1
Zhou, F., Zhu, W., Chen, W., & Ruan, L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189643 · Cited by 1
Toda, S., Hiroshima, Y., Iwasaki, H., Kadoya, M., Suzuki, C., Yamazaki, H., Okubo, Y., Saito, A., & Masudo, K. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00520 · Cited by 1
Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data
Waguespack, S. G., Brose, M. S., Lin, J. J., McDermott, R., Almubarak, M., Bauman, J. R., Casanova, M., Kummar, S., Lee, S.-H., Rieke, D. T., et al. (2026) · Endocrine Related Cancer · doi:10.1530/erc-25-0531 · Cited by 1
Self-citationTatarano, S., Mitsuke, A., Osako, Y., Sakaguchi, T., Inoguchi, S., Matsushita, R., Yoshino, H., Yamada, Y., & Enokida, H. (2026) · Journal of Medical Case Reports · doi:10.1186/s13256-026-06332-0 · Cited by 1
Liu, L., 陈颖君, Guo, M., Yun, F., Li, X., Chen, L., Li, Y. M., & Li, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1782130 · Cited by 1
SEOM‑GETTHI clinical guideline for the practical management of molecular platforms (update 2026)
Salas, N. R., de la Haba-Rodríguez, J., Lloret, F. F., Salgado, M. Á. V., Oré-Arce, M., Cardeña-Gutiérrez, A., Zambrano, C. B., Rodríguez-Alonso, R. M., López‐López, R., & Jiménez, J. G.-D. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04520-4 · Cited by 1
Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges
Habib, R., Arnold, E., Obi, T., Vizeacoumar, F. J., & Ahmed, S. (2026) · Current Oncology · doi:10.3390/curroncol33080452 · Cited by 1
Targeting tumour–neuron synapses with intracavitary RNA delivery prevents glioblastoma recurrence
Li, Z., Hao, Z.-Z., Zhang, Y., Xu, N., Tiebao, M., Jiao, H., Wang, C., Chen, F., Xie, Y., Wang, C., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01757-w · Cited by 1
Li, Y., & He, Z. (2026) · Cancer Innovation · doi:10.1002/cai2.70078 · Cited by 1
du Rusquec, P., Dupain, C., Geiss, R., Sablin, M., Ajgal, Z. C., Cassier, P. A., Italiano, A., Borcoman, É., Klijanienko, J., Servois, V., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-26-0225 · Cited by 1
Emerging Treatment Options for the Management of Metastatic Colorectal Cancer
Deming, D. A. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.5016 · Cited by 1
甲状腺癌のゲノム医療：precision medicineを目指して
信, 田. (2020) · 日本内分泌・甲状腺外科学会雑誌 · doi:10.11226/jaesjsts.37.2_110 · Cited by 1
Congenital Mesoblastic Nephroma
D, S. M. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-58710-9_56 · Cited by 1
Kolangiokarsinom behandlet med tumoragnostisk legemiddel
Thorsteinsdottir, T., & Brustugun, O. T. (2021) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.21.0064 · Cited by 1
Abdayem, P., & Planchard, D. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00107-5 · Cited by 1
Current options and future directions of systemic therapy for advanced biliary tract cancer
Prete, M. G., Cammarota, A., D’Alessio, A., Zanuso, V., & Rimassa, L. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00054 · Cited by 1
Schöche, J., & Niedersüß‐Beke, D. (2022) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00787-1 · Cited by 1
Accès aux tests génétiques en oncologie
Ducreux, M. P., & Amiel, P. (2022) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2022.01.021 · Cited by 1
Артамонова, Е. В., Breder, V. V., Vladimirova, L. Y., Демидова, И. А., Имянитов, Е. Н., Лактионов, К. К., Matrosova, M. P., Орлов, С. В., Родионов, Е. О., Sakaeva, D., et al. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-9-50-56 · Cited by 1
PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma
Chapin, W. J., & Reiss, K. A. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.07.007 · Cited by 1
Myxoid spindle cell sarcoma with ETV6‐NTRK3 fusion
Kyriazoglou, A. I., Dimitriadis, E., Mahaira, L., Kotsantis, J., Kouloulias, V., Kontogeorgakos, V. A., Psyrri, A. K., & Agrogiannis, G. (2022) · Cancer Genetics · doi:10.1016/j.cancergen.2022.09.012 · Cited by 1
Systemic Therapy in Thyroid Cancer
Babu, G., Ravikumar, R., Rafi, M., Nair, L. M., Sharafuddin, Z., Mathew, J. M., Jose, N., & Thommachan, K. C. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106462 · Cited by 1
Zielgerichtete Therapie des Pankreaskarzinoms
Witte, D. P., Dorman, K., Zhang, D., & Westphalen, C. B. (2023) · Die Onkologie · doi:10.1007/s00761-023-01385-y · Cited by 1
Recent Update of Targeted Therapy in Cholangiocarcinoma
Lee, J., & Kim, D. U. (2023) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2023.28.3.59 · Cited by 1
Oh, G., Dhara, S., & Simeone, D. M. (2023) · Wiley eBooks · doi:10.1002/9781119876007.ch152 · Cited by 1
Lema, M., Quintero, N. E. L., Bravo-González, A., & Hernández, J. C. (2023) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.407 · Cited by 1
Stradomskaya, T. V., Suleymanova, A. M., Коновалов, Д. М., Druy, A. E., Панферова, А. В., Preobrazhenskaya, E. V., Андреева, Н. А., Sagoyan, G. B., Teleshova, M. V., Smirnova, L. A., et al. (2023) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/1726-1708-2023-22-3-104-120 · Cited by 1
Molecular pathology of gastrointestinal stromal tumors
Castellano, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822824-1.00020-1 · Cited by 1
Molecular biomarkers in pancreatic ductal adenocarcinoma
Tsuboi, J., Yamada, R., & HIROKAWA, Y. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95114-2.00016-9 · Cited by 1
Innovative therapeutic concepts for biliary tumors
Djanani, A. M. (2024) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-023-00956-4 · Cited by 1
Berchem, G., & Peters, S. (2024) · Springer eBooks · doi:10.1007/978-3-030-93702-7_3-1 · Cited by 1
How to incorporate new agents into precise medicine for cholangiocarcinoma?
Li, Y. (2024) · American Journal of Cancer Research · doi:10.62347/nfdl2398 · Cited by 1
Molecular basis of uterine mesenchymal tumours
Ferozepurwalla, Z., & Ralte, A. M. (2024) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2024.06.002 · Cited by 1
Integration of NGS testing with conventional molecular genetic methods in oncology
Shatalov, P. A., Veselovsky, E., Raigorodskaya, M. P., Shinkarkina, A. P., Murzaeva, A. V., Doroshenko, Y. Y., Averinskaya, D. A., Traspov, A. A., Каприн, А. Д., & Shegai, P. (2024) · P A Herzen Journal of Oncology · doi:10.17116/onkolog20241306184 · Cited by 1
Cardesa‐Salzmann, T. M., Sparber‐Sauer, M., Hingst, P., Erbersdobler, A., Schneider, B., Hühns, M., Jakob, A., Terpe, F., Spang, C., Stalmann, D., et al. (2024) · Head & Neck · doi:10.1002/hed.28058 · Cited by 1
Kim, S., Itani, M., Liu, X., Sun, L., Krysiak, K., Fox, N., Firwana, B., Diffalha, S. A., Manne, U., Seeber, A., et al. (2025) · JCO Precision Oncology · doi:10.1200/po.24.00305 · Cited by 1
Mao, Y., Ye, F., Jiang, Q., Liu, S., & Gong, Y. (2025) · Medicine · doi:10.1097/md.0000000000041835 · Cited by 1
Salim, Y., Herliani, E., & Hasan, R. I. (2023) · Journal Markcount Finance · doi:10.70177/jmf.v1i3.88 · Cited by 1
Cancer genome profiling of prostate cancer identifies a patient with a novel EFNA1–NTRK1 fusion gene
Kanaki, T., Hatano, K., Tahara, S., Ishizuya, Y., Hayashi, T., Yamamoto, Y., Kato, T., Kawashima, A., Takada, T., & Nonomura, N. (2025) · International Cancer Conference Journal · doi:10.1007/s13691-025-00769-8 · Cited by 1
Nakao, T., Fukuda, N., Wang, X., Oki, R., Urasaki, T., Nakano, K., Ono, M., Tomomatsu, J., Ariyasu, R., Sato, Y., et al. (2025) · International Cancer Conference Journal · doi:10.1007/s13691-025-00806-6 · Cited by 1
Nagano, H., Ohyama, S., Satō, A., Igarashi, J., Yamamoto, T., & Kobayashi, M. (2025) · Current Oncology · doi:10.3390/curroncol32090506 · Cited by 1
Patel, R. T., & Deeken, J. F. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04829-x · Cited by 1
Update zur Therapie bei gastroenteropankreatischen neuroendokrinen Karzinomen (GEP-NEC)
Apostolidis, L., & Krug, S. (2025) · Die Gastroenterologie · doi:10.1007/s11377-025-00946-4 · Cited by 1
ASCO 2021: Highlights in central nervous system tumors
Mair, M. J., & Berghoff, A. S. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00752-y · Cited by 1
Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies
Loh, J., Ang, Y. L. E., Jain, A., Yeong, J. P.-S., & Sundar, R. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00208 · Cited by 1
Standard-verändernde Neuigkeiten aus der internistischen Onkologie
Zschäbitz, S., Busch, E., Woydack, L., & Jäger, D. (2020) · Der Klinikarzt · doi:10.1055/a-1278-5795
Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?
Passiglia, F., & Novello, S. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-2019-cnsclc-14
Büchler, T., Dundr, P., Fínek, J., Kišš, I., Matěj, R., Melichar, B., Michal, M., & Petruzelka, L. B. (2020) · Klinicka onkologie · doi:10.48095/ccko2020414
Comprensión del cáncer desde la genética
Patiño, A. R. (2021) · Medicina · doi:10.56050/01205498.1574
Romagnol, F. T., Caran, E. M. M., Romagnol, F. T., Cavalheiro, S., Petrilli, M. D. T., Lederman, H. M., de Lima, F. T., Alves, M. T. D. S., Carreira, L. Y., & Petrilli, A. S. (2021) · Clinical Oncology and Research · doi:10.31487/j.cor.2021.03.03
Pauwels, P., Broeckx, G., Dedeurwaerdere, F., Galant, C., Hébrant, A., Bempt, I. V., de Vijver, K. K. V., Huysse, J. V., Weynand, B., & D’Haene, N. (2021) · Ghent University Academic Bibliography (Ghent University)
Dhanushkodi, M., & Bajpai, J. (2021) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0041-1732823
Einfluss der Molekularpathologie auf die onkologische Chirurgie des Pankreaskarzinoms
Roth, S., & Hackert, T. (2021) · Der Chirurg · doi:10.1007/s00104-021-01485-8
Implementing somatic mutation testing in clinical setting: recommendations from a panel of experts.
Cordeiro-de-Lima, V. C., Araujo, L. H., Garicochea, B., Rocha, V., Mano, M. S., William, W. N., Chaves, A. L. F., Fernandes, G. D. S., Nogueira‐Rodrigues, A., Jardim, D. L. F., et al. (2021) · Brazilian Journal of Oncology · doi:10.5935/2526-8732.20210019
Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients
Dosso, S. D., Siebenhüner, A. R., Winder, T., Meisel, A., Fritsch, R., Astaras, C., Szturz, P., & Borner, M. (2021) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2021.08.032
Vošmik, M., Kopecký, J., John, S., Kubeček, O., Lochman, P., Banni, A. M., Hruška, L., & Sirák, I. (2021) · Cancers · doi:10.3390/cancers13184591
Präzisionsonkologie und Phase-I/II-Netzwerke in der Kinderkrebsmedizin
Nesper‐Brock, M., Metzler, M., Reinhardt, D., Rutkowski, S., Thorwarth, A., van Tilburg, C. M., Pfister, S. M., Schrappe, M., & Witt, O. (2021) · Forum · doi:10.1007/s12312-021-01005-z
Self-citationAn Update on Targeted Therapy in Advanced Non-small Cell Lung Cancer
Ichihara, E. (2021) · Haigan · doi:10.2482/haigan.61.377
Cancer of Unknown Primary: Diagnosis and Treatment
Kim, Y. S., & Lee, S. I. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.5.408
Андреевич, К. А., Andriyanova, A. I., & Филипенко, М. Л. (2022) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2021-20-6-120-133
Joyon, N. (2022) · Annales de Pathologie · doi:10.1016/j.annpat.2022.01.011
Klinische Studien auf der Basis molekularer Charakterisierung von Tumoren
Dittrich, C. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_389-1
Methoden klinischer Prüfung in der Onkologie
Dittrich, C., Edler, L., & SINDERMANN, H. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_362-1
Response to immune checkpoint inhibitor combined therapies in metastatic BRAF mutant lung cancersPreprint
Yan, N., Zhang, Z., Guo, S., Huang, S., Shen, S., Xu, L., Zhang, H., & Li, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1551063/v1
Clinical decision-making strategies for rare somatic variants in cancer
Koopman, H. F. J. M. (2022) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.213504207
Tumor genetics and individualized therapy
Hlevnjak, M. (2022) · Die Gynäkologie · doi:10.1007/s00129-022-04931-8
Su, D. W., Pan, J., Shahab, N., Le, H., Malhotra, K., & Patel, T. C. (2022) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2022.100158
Neurological complications of lung cancer
Kaulen, L. D., Lu, B. Y., Goldberg, S. B., & Baehring, J. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821976-8.00027-x
Cao, C. D., & Lion, G. (2022) · Elsevier eBooks · doi:10.1016/b978-2-294-77583-3.00010-1
Therapy of non-iodine uptaking metastasis in thyroid cancer
Grani, G., Sponziello, M., Verrienti, A., & Durante, C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822960-6.00201-5
Renovanz, M., Rieger, J., Skardelly, M., & Tabatabai, G. (2022) · TumorDiagnostik & Therapie · doi:10.1055/a-1727-3018
NTRK Inhibitors in Adult Patients with Solid Tumors
DioGuardi, M., Evans, R., & Fountzilas, C. K. (2022) · Advances in Oncology · doi:10.1016/j.yao.2022.02.010
Advanced Thyroid Carcinoma: Evolving Systemic Therapy Options
Wirth, L. J. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.5018
(2022) · Wiley eBooks · doi:10.1002/9783527838561.ch18
New drug: Eptinezumab for migraine
(2022) · Australian Prescriber · doi:10.18773/austprescr.2022.030
Four cases of secretory carcinoma of the salivary gland
Shino, M., Sato, R., Ida, S., Nikkuni, O., & Chikamatsu, K. (2022) · JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY · doi:10.5106/jjshns.32.53
Lemelle, L., Guillemot, D., Hermann, A.-L., Gauthier, A., Carton, M., Corradini, N., Rome, A., Berlanga, P., Jourdain, A., Cardine, A. M., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4096543
Self-citationAspectos clínicos y terapéuticos del carcinoma de mama metastásico triple negativo
Olvera, J. A. S., Pérez, D. O., Noguez-Ramos, A., Medina, R. G. R., Cantero, A. J., & de la Borbolla, L. F. M.-C. (2022) · Anales Médicos de la Asociación Médica del Centro Médico ABC · doi:10.35366/106027
Distribution and Outcome of NTRK-Rearranged Mesenchymal Tumors (NMT): An Ambispective Cases SeriesPreprint
Dufresne, A., Pissaloux, D., Ngo, C., Penel, N., Cesne, A. L., Macagno, N., Vanacker, H., Jean‐Denis, M., Tirode, F., Blay, J., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4175182
Challenges in biomarker-based clinical trials for patients with gastrointestinal malignancies
Kratz, J. D., Zhang, W., Patel, M. A., & Uboha, N. V. (2022) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2022.2106852
Vera, R., de Andrés, C. I., Adeva, J., Pérez‐Rojas, J., Alfonso, P. G., Rodriguez-Gil, Y., Macarulla, T. M., Piñol, T. S., Mondéjar, R., & Madrigal-Rubiales, B. (2022) · Revista Española de Patología · doi:10.1016/j.patol.2022.06.004
Biomarkers in Head and Neck Cancer
Oaks, Z. A., Shen, C. J., Sheth, S. H., Gupta, G. P., & Chera, B. S. (2022) · Springer eBooks · doi:10.1007/978-3-031-05973-5_9
Marina, M., Marina, M., Belen, P. L., Marti, J. L., Innocenti, S., Luz, R. P. M., Walter, C., Felizzia, G., Viso, M., Pedro, Z., et al. (2022) · Surgical Case Reports · doi:10.31487/j.scr.2022.09.02
Morgensztern, D., Boffa, D. J., Chen, A. J., Dhanasopon, A. P., Goldberg, S. B., Decker, R. H., Devarakonda, S. H. K., Ko, J. P., Soto, L. M. S., Waqar, S. N., et al. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm085.pub2
Speicheldrüsentumoren – eine interdisziplinäre Herausforderung
Schneider, F., Becker, S., Böke, S., Hoefert, S., & Schneidawind, D. (2022) · TumorDiagnostik & Therapie · doi:10.1055/a-1915-3374
Approach and Management of Anaplastic Carcinoma Thyroid
Sharafuddin, Z., Ravikumar, R., Rafi, M., Nair, L. M., Mathew, J. M., & Thommachan, K. C. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106463
Pathologische Grundlagen und Anforderungen
Boxberg, M., & Weichert, W. (2022) · Springer eBooks · doi:10.1007/978-3-662-62808-9_2
Metadata
- Authors
- Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., Mascarenhas, L., Geoerger, B., Dowlati, A., Pappo, A. S., Bielack, S., Doz, F., McDermott, R., Patel, J. D., Schilder, R. J., Tahara, M., Pfister, S. M., Witt, O., Ladanyi, M., Rudzinski, E. R., Nanda, S., Childs, B. H., Laetsch, T. W., Hyman, D. M., & Drilon, A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Stanford Medicine (US)
- Massachusetts General Hospital (US)
- Seattle Children's Hospital (US)
- University of Copenhagen (DK)
- Vanderbilt University Medical Center (US)
- University of California, Los Angeles (US)
- University of Southern California (US)
- Université Paris-Saclay (FR)
- University Hospitals Cleveland Medical Center (US)
- St. Jude Children's Research Hospital (US)
- Olgahospital (DE)
- Université Paris Descartes (FR)
- Cancer Trials Ireland (IE)
- University of Chicago (US)
- Thomas Jefferson University (US)
- National Cancer Center Hospital East (JP)
- German Cancer Research Center (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Bayer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Drilon, Alexander
- ORCID
- Hong, David S
- DuBois, Steven G
- Kummar, Shivaani
- Farago, Anna F
- Albert, Catherine M
- Rohrberg, Kristoffer S
- Nagasubramanian, Ramamoorthy
- Berlin, Jordan D
- Federman, Noah
- Mascarenhas, Leo
- Geoerger, Birgit
- Dowlati, Afshin
- Pappo, Alberto S
- Bielack, Stefan
- Doz, François
- McDermott, Ray
- Patel, Jyoti D
- Tahara, Makoto
- Pfister, Stefan M
- Witt, Olaf
- Ladanyi, Marc
- Rudzinski, Erin R
- Nanda, Shivani
- Childs, Barrett H
- Laetsch, Theodore W
- Hyman, David M
- Drilon, Alexander
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 21
- Issue
- 4
- Pages
- 531-540
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC7497841
- OpenAlex
- W3008107700
- Cited by
- 1,028
- References
- 25
- Citations by year
- 2026: 106 · 2025: 148 · 2024: 162 · 2023: 178 · 2022: 202 · 2021: 171 · 2020: 60
- FWCI
- 86.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Loxo Oncology
- Bayer Corporation
- Bayer Fund
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- larotrectinib, TRK inhibitors, objective response rate, long-term safety, adverse events, childhood cancer, adult cancer, metastatic cancer, pooled analysis of clinical trials, alanine aminotransferase elevation, neutropenia, anemia, complete response, dose-limiting toxicity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Neoplasms, Proteins, Pyrazoles, Pyrimidines, Vesicular Transport Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
